Get started
vTv Therapeutics Inc.vTv Therapeutics Inc.vTv Therapeutics Inc.

vTv Therapeutics Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VTVT chart


Full chart

VTVT upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪65.55 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.41 USD
Net income (FY)
‪−18.46 M‬ USD
Revenue (FY)
‪1.02 M‬ USD
Shares float
‪1.48 M‬
Beta (1Y)
1.33

Employees


Employees (FY)
23
Change (1Y)
+7 +43.75%
Revenue / Employee (1Y)
‪44.22 K‬ USD
Net income / Employee (1Y)
‪−802.70 K‬ USD

About vTv Therapeutics Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Paul Jai Sekhri
Website
vtvtherapeutics.com
Headquarters
High Point
Founded
2015
FIGI
BBG009DT9XJ0
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VTVT news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as VTVT.

Frequently Asked Questions


The current price of VTVT is 22.50 USD — it has increased by 2.36% in the past 24 hours. Watch vTv Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange vTv Therapeutics Inc. stocks are traded under the ticker VTVT.
VTVT stock has risen by 11.47% compared to the previous week, the month change is a 23.74% rise, over the last year vTv Therapeutics Inc. has showed a −8.65% decrease.
We've gathered analysts' opinions on vTv Therapeutics Inc. future price: according to them, VTVT price has a max estimate of 36.00 USD and a min estimate of 35.00 USD. Watch VTVT chart and read a more detailed vTv Therapeutics Inc. stock forecast: see what analysts think of vTv Therapeutics Inc. and suggest that you do with its stocks.
VTVT reached its all-time high on Jul 30, 2015 with the price of 560.00 USD, and its all-time low was 7.38 USD and was reached on Jan 26, 2024. View more price dynamics on VTVT chart.
See other stocks reaching their highest and lowest prices.
VTVT stock is 10.54% volatile and has beta coefficient of 1.33. Track vTv Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is vTv Therapeutics Inc. there?
Today vTv Therapeutics Inc. has the market capitalization of ‪53.68 M‬, it has increased by 4.95% over the last week.
Yes, you can track vTv Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
vTv Therapeutics Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
VTVT earnings for the last quarter are −0.55 USD per share, whereas the estimation was −0.87 USD resulting in a 36.78% surprise. The estimated earnings for the next quarter are −0.81 USD per share. See more details about vTv Therapeutics Inc. earnings.
vTv Therapeutics Inc. revenue for the last quarter amounts to ‪17.00 K‬ USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
VTVT net income for the last quarter is ‪−3.63 M‬ USD, while the quarter before that showed ‪−4.78 M‬ USD of net income which accounts for 24.02% change. Track more vTv Therapeutics Inc. financial stats to get the full picture.
No, VTVT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 24, 2025, the company has 23 employees. See our rating of the largest employees — is vTv Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. vTv Therapeutics Inc. EBITDA is ‪−24.09 M‬ USD, and current EBITDA margin is ‪−2.37 K‬%. See more stats in vTv Therapeutics Inc. financial statements.
Like other stocks, VTVT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade vTv Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So vTv Therapeutics Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating vTv Therapeutics Inc. stock shows the buy signal. See more of vTv Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.